BioNTech SE (BNTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Mainz, Germany. The current CEO is Ugur Sahin.
BNTX has IPO date of 2019-10-10, 6,772 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $24.73B.
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, that develops and commercializes immunotherapies targeting cancer and infectious diseases. The company's pipeline includes multiple therapeutic programs: personalized cancer vaccines (FixVac candidates), neoantigen-specific immunotherapies including Autogene cevumeran, mRNA intratumoral immunotherapies, chimeric antigen receptor T cell therapies, checkpoint immunomodulators, and monoclonal antibodies, with most candidates in clinical development stages. BioNTech also develops prophylactic vaccines for COVID-19 and influenza, along with therapies for rare diseases. The company maintains strategic collaborations with major pharmaceutical and biotechnology partners including Pfizer, Sanofi, Genentech, Regeneron, and others to advance its diverse clinical pipeline.
